De-Bunking the Opioid Litigation Epidemic

by Kelley Drye & Warren LLP
Contact

If you type ‘opioids’ into a search engine, chances are you’ll be greeted with headlines like: “Opioid abuse is in everyone’s backyard”.  The Washington Post writes: “Even this puppy wasn’t safe from America’s opioid crisis”; and on NBCNews you can read, “Born Addicted: The number of opioid-addicted babies is soaring.”  It seems that, according to every news source in America, the time for tempered rhetoric is over. The opioid crisis has been declared a “national health emergency.”

Sensational story lines sell newspapers and generate hits on websites.  Currently, the pharmaceutical industry—which manufactures and distributes medicine that for many provide vital relief from chronic, agonizing pain—is being cast by the media, and litigants, as the cause of a national crisis.  But the causes of the Opioid Epidemic are complex which is reflected in the science.  There may not even be an “epidemic”.

The Science

Most people who are prescribed opioids use their medication without incident.  In fact, data from the National Survey on Drug Use and Health shows that only 1 to 2 percent of the 98 million prescription opioid users are likely to become addicted in any one year.  A fraction of those may die from overdose.  Other data suggests overdoses involve combinations of drugs (over 90% of overdoses in New York).

The Office of the Inspector General has published reports demonstrating that a relatively small number of doctors and pharmacists are responsible for a disproportionate number of prescriptions.  In 2016, the OIG identified 400 prescribers who had “questionable opioid prescribing patterns” involving beneficiaries who were at a high risk of opioid abuse.  While this is a small number in the vast pool of competent medical practitioners, it amounts to a potential 90,000 prescriptions to high-risk individuals given out in all.

Other health factors must be considered as well.  A report by Coverys found that 24% of medication related medical malpractice suits involved the prescription of opioids; about a third of those claims are ascribed to errors in the ordering process; another third to errors in administration and prescription; and a final third to negligent management and monitoring.  (The next greatest source of litigation was coagulants with 16% of suits.)

Newer studies are exploring the relationship between prescription opioid abuse and mood disorders.  A 2017 study in the Journal of Substance Abuse found that an astounding 81% of patients with chronic pain have mood disorders.  These individuals, studies have shown, get much less pain relief from their opioid consumption than do those without mood disorders. Bearing this out: patients with depression are twice as likely to abuse opioids. Of patients whose deaths were ascribed to prescription opioids, 56% had a history of mental illness; 45% had been hospitalized for psychiatric reasons. 

A history of drug abuse can also be a significant indicator of future opioid addiction.  A 2015 study in Addictive Behaviors, found that the greatest predictor for whether a person is likely to abuse pain-relieving opioids is whether they have used illicit drugs in the last year.  Amongst those seeking treatment for OxyContin addiction, 78% had previously sought treatment for another drug addiction, according to a study published in the American Journal of Psychiatry.

Of course, the same percentage (78%) had never had a prescription for OxyContin at all, and had thus entirely bypassed the legal, ostensibly regulated healthcare system through which pharmaceutical companies, and those with medically recognized chronic pain, should operate.

The Litigation

From a legal perspective, these facts undermine the case against pharmaceutical companies.  An element of any claim is causation—that the harm was caused by the wrongful action of the charged party.  The causes and effects of the opioid crisis are not simple or linear.

Keeping You Updated

For more on this, and other topics related to the Opioid Litigation Epidemic, follow our on-going coverage, and click here if you would like more in-depth updates on this legal phenomenon as it progresses.

[View source.]

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Kelley Drye & Warren LLP | Attorney Advertising

Written by:

Kelley Drye & Warren LLP
Contact
more
less

Kelley Drye & Warren LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.